VivoSeq
Cardiovascular

Cardiovascular Disease

239

Pipeline Programs↗

39

Active Trials↗

82

Companies Involved↗

Cardiovascular Disease is a highly competitive landscape with 239 programs across 82 companies. The most active players are Mylan Pharmaceuticals Inc, Eisai, Melinta Therapeutics, Inc.. 115 therapies are approved with 51 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

83/100

Pipeline Velocity

25/100

Mech. Concentration

7/100

Completion Rate

85/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Mylan Pharmaceuticals Inc logo

Mylan Pharmaceuticals Inc

1 program

Phase 1Eisai logo

Eisai

1 program

Phase 1M

Melinta Therapeutics, Inc.

1 program

Phase 1A

Akcea Therapeutics

1 program

Phase 2S

Silence Therapeutics plc

1 program

Phase 2M

Menarini International Operations Luxembourg SA

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical42

Norepinephrine

General Hospital of Ningxia Medical University

Levosimendan

Orion Corporation, Orion Pharma

Candesartan

AstraZeneca

Tirzepatide

Eli Lilly

Alirocumab

Regeneron

Phase 113

Albuterol Sulfate

Mylan Pharmaceuticals Inc

Lorcaserin

Eisai

Fx-5a Peptide Complex

National Heart, Lung, and Blood Institute (NHLBI)

AZD4831

AstraZeneca

Antibiotics

Melinta Therapeutics, Inc.

Phase 218

Ranolazine

Menarini International Operations Luxembourg SA

LY2228820

Eli Lilly

Spironolactone

Pfizer

Ticagrelor

AstraZeneca

Hydroxychloroquine

Alnylam Pharmaceuticals

Phase 351

Exenatide

AstraZeneca

Orforglipron

Eli Lilly

Rimonabant

Sanofi

Bempedoic Acid

Esperion Therapeutics, Inc.

Cagrilintide

Novo Nordisk

Approved115

Tocilizumab

Roche

Nifedipine

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Tolvaptan

Otsuka

Warfarin

Abbott

Nebivolol

Vitae Pharmaceuticals Inc., an Allergan affiliate

Analysis

Modality Breakdown

91%

Small molecule

243 of 266 classified programs — the dominant modality here.

9%ALL OTHERSPeptide104%RNA therapy62%Monoclonal antibody42%Protein / enzyme31%

Small molecule leads; the ring shows all 266 classified programs, each share of the total. Modality classified for 100% of 275 pipeline programs.

Analysis

Trial Status

161

clinical trials

Completed85 · 53%
Unknown status22 · 14%
Recruiting17 · 11%
Active, not recruiting12 · 7%
Terminated10 · 6%
Not yet recruiting8 · 5%
Other7 · 4%

Clinical Trials

Trial Activity

161 trials

Mitigation of Cardiovascular Disease Risks in Children With Extreme Obesity
Recruiting·—·N/A·NCT06967389·50 enrolled
Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes
Recruiting·SSteno Diabetes Center Copenhagen·Phase 3·NCT06082063·2,000 enrolled
Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia
Recruiting·Novartis logoNovartis·N/A·NCT06858332·2,382 enrolled
Effect of Intensive LDL-cholesterol Targeting for Elderly Patients With Cardiovascular Disease: I-OLD Trial
Recruiting·YYonsei University·Phase 4·NCT05361421·1,200 enrolled
Secondhand Tobacco Smoke and Cardiovascular Disease
Recruiting·UUniversity of California, San Francisco·Phase 4·NCT04715568·100 enrolled
Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease
Recruiting·HHospital do Coracao·Phase 3·NCT06930885·7,713 enrolled
Effects of Vitamin D3 and Yeast Beta-Glucan Supplementation on Glycemic Control and Cardiovascular Disease Risk in Patients With Type 2 Diabetes
Recruiting·HHuazhong University of Science and Technology·N/A·NCT06861062·2,500 enrolled
Evaluating the Impact of 'Tertinat' on Patients with Atherosclerosis-Related Cardiovascular Diseases
Recruiting·IInstitute for Atherosclerosis Research, Russia·Phase 2·NCT06590012·556 enrolled
Emulation of Randomized Clinical Trial in Cardiovascular Disease
Recruiting·SSamsung Medical Center·N/A·NCT06241833·118,420 enrolled
Cardiovascular Disease Risk in Women With Endometriosis
Recruiting·YYale University·Phase 1·NCT03746535·40 enrolled
Cohort Study on Treatment of Cardiovascular Diseases With Traditional Chinese Medicine
Recruiting·TTianjin University of Traditional Chinese Medicine·N/A·NCT05309343·20,000 enrolled
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a)
Recruiting·Amgen logoAmgen·Phase 3·NCT07136012·11,000 enrolled
A Single Arm, Multicenter, Open-label Extension (OLE) Trial to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) in Participants Who Completed the Parent Lp(a)HORIZON Trial
Recruiting·Novartis logoNovartis·Phase 3·NCT07517263·5,700 enrolled
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients With Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event
Recruiting·AstraZeneca logoAstraZeneca·Phase 3·NCT07000357·15,100 enrolled
Natural History Study of CADASIL
Recruiting·National Heart, Lung, and Blood Institute (NHLBI)·N/A·NCT05072483·155 enrolled
Page 1 of 11

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)